Is concomitant splenectomy beneficial for the long-term survival of patients with gastric cancer undergoing curative gastrectomy? A single-institution study by Hao Zhang et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Zhang et al. World Journal of Surgical Oncology 2014, 12:193
http://www.wjso.com/content/12/1/193RESEARCH Open AccessIs concomitant splenectomy beneficial for the
long-term survival of patients with gastric
cancer undergoing curative gastrectomy?
A single-institution study
Hao Zhang1, Deyan Pang2, Huanming Xu3, Yuan Ren4 and Caigang Liu1*Abstract
Background: Curative resection is the treatment of choice for gastric cancer, but it is unclear whether gastrectomy
should also include splenectomy. We retrospectively analyzed long-term survival in patients in our hospital who
underwent gastrectomy plus splenectomy (G + S) or gastrectomy alone (G-A) for gastric cancer.
Methods: We identified 214 patients who underwent surgery with curative intent between 1980 and 2003. Of
these, 100 underwent G + S, and 114 underwent G-A. The primary endpoint was 5-year overall survival (OS).
Results: Median follow-up was 18 months in patients who underwent G + S, and 26.5 months in patients who
underwent G-A. The 5-year OS rate was significantly higher in patients who underwent G-A (33.8%; 95% CI 24.2 to
43.4%) than in those who underwent G + S (28.8%; 95% CI 19.6 to 38.0%) (log-rank test, P = 0.013).
Conclusions: Splenectomy does not benefit patients undergoing gastrectomy for gastric cancer. Routine
splenectomy should be abandoned in patients undergoing radical resections for gastric cancer.
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Gastric cancer remains the most common cause of
cancer-related deaths worldwide, with poor patient
prognosis and a lack of adequate treatment methods.
Although surgical resection is the primary treatment
method for gastric cancer, more extensive surgery is
accompanied by greater risks of surgery-related mor-
bidity and mortality [1]. The mortality rate for patients
undergoing gastrectomy surgery in western countries
often exceeds 5%, and may be as high as 16% [2],
although the rate in Japanese patients has been
reported as being less than 2% [3]. Moreover, the
efficacy of concomitant splenectomy remains unclear.
As our understanding of the role of the spleen in the
immunological defenses of the body and in the preven-
tion of sepsis has increased, the value of routine* Correspondence: yincailove@126.com
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reproduction in any medium, provided the orremoval of the spleen, en bloc with the stomach, during
the course of radical, potentially curative resection for
gastric cancer has been reassessed.
In this study, we retrospectively analyzed long-term
survival data of patients who underwent gastrectomy,
with or without splenectomy, for gastric cancer at a
single institution. We found that operative complica-
tion rates were significantly higher in patients under-
going concomitant splenectomy, and it carried no
benefit to patients already undergoing gastrectomy.
Consequently, we believe, its routine use in radical
resection for gastric cancer should be abandoned.Methods
Patients
We identified 214 patients with histologically confirmed
gastric cancer who had undergone radical surgery at the
First Affiliated Hospital of China Medical University
between 1980 and 2003, Patients were included in the
study if they: 1) had histologically confirmed gastricLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Characteristics of patients undergoing
gastrectomy with and without splenectomy (n = 214)a
Characteristic G + S (n = 100) G-A (n = 114) P-value
Age, years 0.836
≤ 55 32 (32) 38 (33)
> 55 68 (68) 76 (67)
Sex 0.190
Men 82 (82) 85 (75)
Women 18 (18) 29 (25)
Tumor size, cm 0.393
≤ 4 23 (23) 27 (24)
5 to 6 26 (26) 21 (18)
> 6 51 (51) 66 (58)
Pathological tumor stage 0.600
T1 5 (9) 8 (9)
T2 28 (49) 45 (53)
T3 16 (28) 26 (31)
T4 8 (14) 6 (7)
Pathological nodal stage 0.153
N0 10 (15) 24 (28)
N1 20 (31) 29 (34)
N2 23 (35) 23 (27)
N3 12 (19) 9 (11)
TNM stage 0.355
IA 2 (2) 5 (4)
IB 19 (19) 23 (20)
II 18 (18) 30 (26)
IIIA 29 (29) 31 (27)
IIIB 14 (14) 14 (12)
IV 18 (18) 11 (10)
Gross type (Borrman) 0.154
I 3 (3) 2 (2)
II 20 (20) 12 (11)
III 59 (60) 66 (61)
IV 17 (17) 29 (27)
Type of gastrectomy 0.958
Total 60 (60) 68 (60)
Sub-total 40 (40) 46 (40)
Complications 24 (24) 11 (10) 0.005c
Adjunctive therapy 12 (12) 14 (12) 0.903
Abbreviations: G + S gastrectomy plus splenectomy, G-A gastrectomy alone,
TMN tumor, node, metastasis.
aData are given as n (%).
cSignificant.
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complete medical record available; and 4) had never
received neoadjuvant therapies. The number of pa-
tients at every period of diagnosis and the number
treated by each surgeon were roughly equal.
All patients were followed up by mail or telephone
interviews, and the final follow-up was in December
2008. Clinical, surgical, and pathological findings at the
time of surgery and at each follow-up were collected
and recorded in the database.
Ethics approval
The study protocol was approved by the Ethics Commit-
tee of China Medical University. [The patients signed the
informed consent about operation and so on routinly, we
don’t need another consent about this study any more].
Surgical procedures and classifications of gastric cancer
All operations were performed at the First Affiliated
Hospital of China Medical University. Surgical proce-
dures and pathological assessments were standardized in
accordance with the Japanese classification of gastric
cancer [4]. All patients underwent standard total or dis-
tal sub-total gastrectomy, depending on the location and
macroscopic appearance of the primary tumor.
Endpoints and follow-up
The primary endpoint was 5-year overall survival (OS) rate.
OS was calculated from the date of surgery until the date of
death or final follow-up contact. Patients remaining alive at
the date of final follow-up were censored at that point.
Patients were followed up every 6 months for the first
5 years after surgery, and every 12 months thereafter.
Statistical analyses
OS was analyzed in all eligible patients. Survival curves
were determined by the Kaplan–Meier method, and
compared by the log-rank test. Potential prognostic factors
were entered into a Cox regression model. For univariate
analyses, prognostic factors of interest and treatment
group were deemed covariates in the Cox regression
model. Subgroups were analyzed in this model to evaluate
interactions between treatment and subgroup. All P-values
were two-sided, with P < 0.05 considered significant. All
statistical analyses were performed using SPSS software
(version 16.0; SPSS Inc., Chicago, IL, USA).
Results
Of the 214 patients who underwent gastrectomy for
gastric cancer from 1980 to 2003, 100 patients (median
age 59 years) underwent gastrectomy plus splenectomy
(G + S), while the remaining 114 (median age 55.5 years),
underwent gastrectomy alone (G-A). All patients were
followed up for at least 5 years, until December 19, 2008.The baseline demographic and clinical characteris-
tics of the two groups were similar (Table 1). Of the
214 patients, 13 (6.1%) had early gastric cancer (EGC)
confined to the submucosa or mucosa. All patients
Table 2 Complications in patients undergoing
gastrectomy with and without splenectomy (n = 214)a
Complications G + S (n = 100) GA (n = 114)
Intestinal obstruction 1 (1) 3 (3)
Pneumonia 1 (1) 1 (1)
Abdominal abscess 7 (7) 2 (2)
Anastomotic leakage 7 (7) 0 (0)
Other 8 (8) 5 (4)
Abbreviations: G + S gastrectomy plus splenectomy, G-A gastrectomy alone.
aData are given as n (%).
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performed in 60 of the 100 (60%) patients who under-
went G + S, and in 68 of the 114 (60%) who underwent
G-A. Complications were more common (P = 0.005) in
the G + S group than in the gastrectomy-alone group
(Table 1; Table 2). A total of 26 patients, 12% in each
group, received adjuvant chemotherapy after surgery.
The median follow-up durations were 18 months in
the G + S group and 26.5 months in the G-A group. By
the end of follow-up, 87 of the 100 patients (87%) who
underwent G + S and 83 of the 114 (73%) who under-
went G-A had died. Kaplan-Meier analysis of OS inFigure 1 Kaplan-Meier analysis of overall survival (OS) in patients und
gastrectomy alone. The 5-year OS rates in these two groups were 28.8%
(P = 0.013 by the log-rank test).these two groups showed a significant between-group
difference (Figure 1). The 5-year OS rates were 33.8%
(95% CI 24.2 to 43.4%) in the G-A group and 28.8%
(95% CI 19.6 to 38.0%) in the G + S group (p = 0.013 by
the log-rank test).
The hazard ratio (HR) for death was 1.456 (95% CI
1.076 to 1.970; P = 0.015) in the G + S relative to the
G-A group (Table 3). After adjustment for nine baseline
variables (age, sex, tumor size, Borrmann type, T stage,
lymph-node stage, TNM stage, complications and type
of gastrectomy) using Cox regression analysis, the HR
was 1.777 (95% CI 1.137 to 2.777; P = 0.012) (Table 3).
As expected, multivariate analysis showed that Borrmann
type IV and advanced TNM stages were significantly as-
sociated with poor survival (Table 3).
G-A was significantly more beneficial than G + S in
men, and in patients with tumor size >6 cm, Borrmann
type III tumors, or those who underwent subt-otal gas-
trectomy (Table 4). We therefore would not recommend
routine splenectomy in patients with gastric cancer who
require sub-total gastrectomy, unless the tumor lies
close to or directly invades the splenic hilum. Our re-
sults indicate that splenectomy should not be included
in the treatment of patients with curable gastric cancer.ergoing gastrectomy plus splenectomy and those undergoing
(95% CI 19.6 to 38.0%) and 33.8% (95% CI 24.2 to 43.4%), respectively
Table 3 HR for death in the intention-to-treat population (n = 214)
Univariate analyses Multivariate analyses
HR (95% CI) Pa HR (95% CI) Pb
Age, years 0.251 0.242
≤ 55 1 (Ref) 1 (Ref)
> 55 1.212 (0.872 to 1.685) 0.251 1.427 (0.823 to 2.476) 0.242
Sex 0.444 0.473
Women 1 (Ref) 1 (Ref)
Men 0.867 (0.600 to 1.251) 0.444 0.756 (0.430 to 1.328) 0.473
Tumor size, cm 0.000 0.172
≤ 4 1 (Ref) 1 (Ref)
5 to 6 1.492 (0.932 to 2.390) 0.096 1.562 (0.763 to 3.199) 0.222
> 6 2.058 (1.368 to 3.097) 0.001 1.808 (0.928 to 3.522) 0.082
Pathological tumor stage 0.000 0.698
T1 1 (Ref) 1 (Ref)
T2 4.134 (2.968 to 5.756) 0.000 1.484 (0.828 to 2.658) 0.184
T3 6.508 (4.643 to 9.121) 0.000 1.120 (0.409 to 3.066) 0.826
T4 9.231 (5.752 to 14.813) 0.000 1.763 (0.149 to 3.906) 0.745
Pathological nodal stage 0.000 0.413
N0 1 (Ref) 1 (Ref)
N1 2.253 (1.912 to 2.654) 0.000 1.201 (0.764 to 1.888) 0.426
N2 4.128 (3.390 to 5.027) 0.000 1.348 (0.586 to 3.100) 0.482
N3 8.215 (6.301 to 10.711) 0.000 1.722 (0.515 to 5.756) 0.377
TNM stage 0.000 0.016c
IA 1 (Ref) 1 (Ref)
IB 2.402 (1.611 to 3.580) 0.000 2.778 (1.504 to 5.132) 0.001c
II 4.589 (3.148 to 6.690) 0.000 5.461 (2.049 to 14.559) 0.001c
IIIA 8.334 (5.708 to 12.168) 0.000 10.403 (2.567 to 42.162) 0.001c
IIIB 11.148 (7.406 to 16.782) 0.000 13.570 (2.182 to 84.410) 0.005c
IV 18.123 (9.654 to 28.184) 0.000 27.360 (3.028 to 47.256) 0.003c
Gross type (Borrmann) 0.001 0.034c
I 1 (Ref) 0.984 1 (Ref)
II 0.989 (0.343 to 2.853) 3.316 (0.727 to 15.120) 0.122
III 1.337 (0.491 to 3.645) 0.570 3.358 (0.894 to 12.611) 0.073
IV 2.561 (1.909 to 7.210) 0.025 4.584 (1.201 to 17.499) 0.026c
Type of gastrectomy 0.463 0.297
Total 1 (Ref) 1 (Ref)
Sub-total 0.891 (0.654 to 1.213) 0.463 1.139 (0.722 to 1.796) 0.297
Operation 0.015 0.012c
Without splenectomy 1 (Ref) 1 (Ref)
With splenectomy 1.456 (1.076 to 1.970) 0.015 1.777 (1.137 to 2.777) 0.012c
Complications 0.887 0.173
No 1 (Ref) 1 (Ref)
Yes 0.992 (0.894 to 1.101) 0.887 0.502 (0.254 to 1.193) 0.173
Abbreviations: HR hazard ratio, Ref reference category.
aDerived from tests of HR for prognostic factors in univariate model adjusted for type of surgery in a Cox proportional-hazards model.
bCox-regression analysis, controlling for the prognostic factors listed in the table.
cSignificant.
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Table 4 Tests for heterogeneity of treatment effect according to the clinicopathological characteristics of the patients
undergoing gastrectomy with and without splenectomy
Subgroup G + S, patients/total patients, n G-A, patients/total patients, n HR (95% CI)a P-valueb
Deaths 87/100 83/114 1.456 (1.076 to 1.970)
Age, years
≤ 55 26/32 25/38 1.559 (0.897 to 2.709) 0.116
> 55 61/68 58/76 1.377 (0.960 to 1.974) 0.082
Sex
Women 17/18 20/29 1.527 (0.797 to 2.926) 0.201
Men 70/82 63/85 1.433 (1.018 to 2.018) 0.039c
Tumor size, cm
≤ 4 16/23 15/27 1.606 (0.778 to 3.314) 0.200
5 to 6 23/26 18/21 1.135 (0.604 to 2.134) 0.694
> 6 48/51 50/66 1.606 (1.079 to 2.391) 0.019c
Pathological tumor stage
T1 5/5 7/8 3.458 (0.790 to 15.144) 0.100
T2 21/28 30/45 1.478 (0.840 to 2.598) 0.175
T3 14/16 19/26 0.871 (0.426 to 1.781) 0.706
T4 7/8 4/6 1.803 (0.521 to 6.238) 0.352
Pathological nodal stage
N0 7/10 15/24 1.800 (0.707 to 4.586) 0.218
N1 16/20 19/29 1.373 (0.704 to 2.678) 0.353
N2 21/23 19/23 1.221 (0.648 to 2.300) 0.537
N3 11/12 7/9 0.969 (0.345 to 2.722) 0.952
TNM stage
IA 2/2 5/5 2.783 (0.386 to 20.066) 0.310
IB 16/19 14/23 1.433 (0.694 to 2.961) 0.331
II 15/18 21/30 1.875 (0.955 to 3.681) 0.068
IIIA 23/29 22/31 1.027 (0.567 to 1.860) 0.930
IIIB 13/14 13/14 0.800 (0.359 to 1.783) 0.585
IV 18/18 8/11 1.649 (0.706 to 3.850) 0.248
Gross type (Borrmann)
I 2/3 2/2 1.405 (0.125 to 15.838) 0.783
II 18/20 7/12 1.908 (0.790 to 4.609) 0.151
III 50/59 46/66 1.536 (1.028 to 2.296) 0.036c
IV 16/17 23/29 1.623 (0.847 to 3.111) 0.145
Type of gastrectomy
Total 53/60 50/68 1.317 (0.893 to 1.942) 0.165
Sub-total 34/40 33/46 1.700 (1.032 to 2.803) 0.037c
Abbreviations: G + S gastrectomy plus splenectomy, G-A gastrectomy alone, HR hazard ratio, TNM tumor, node, metastasis.
aHR >1 indicates that G-A was superior, whereas HR <1 indicates that G + S was superior.
bThe P-values are for HRs for deaths in each group (G + S or GA), with 95% CI.
cConsidered significantly better for G + S.
Zhang et al. World Journal of Surgical Oncology 2014, 12:193 Page 5 of 7
http://www.wjso.com/content/12/1/193Discussion
The spleen is an organ that protects the host against
infection and perhaps also against tumor microme-
tastases, and knowledge about its immunological
functions has increased markedly in recent years.
Although lymph nodes in the hiluma of the spleen maybe affected by gastric tumors, the spleen itself is
seldom affected. Our retrospective comparison showed
that OS was significantly higher and complication rates
significantly lower in patients undergoing G-A than in
those undergoing G + S for curative resection of gastric
cancer.
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risks of operative morbidity and mortality. We found
that removal of the spleen during the course of resec-
tion for gastric carcinoma significantly increased opera-
tive morbidity rates compared with spleen preservation
(24% versus 10%, P < 0.05). The increased morbidity
after splenectomy may due to the higher incidence of
infectious complications after gastrectomy. Mortality
rates in western countries for patients undergoing gas-
trectomy often exceed 5% and may be as high as 16%
[2]. Thus, G + S should not be considered the standard
curative surgical procedure in patients with gastric
cancer unless the addition of splenectomy is found
to significantly benefit patients by reducing operative
morbidity and mortality rates or improving long-term
survival. In the current study, no evidence was found
that removal of the spleen led to any increase in 5-year
OS rate after potentially curative resection. We found
that the 5-year OS rates were 28.8% in patients under-
going G + S and 33.8% in patients undergoing G-A,
similar to previous findings [4-7]. Splenectomy was also
shown to negatively influence survival, and in addition,
increased length of hospital stay and probability of
death [8-10].
In addition to the extent of the surgery, the opera-
tive skill and experience of the surgeon(s) and the
workload of cases are also important factors for
survival rates [11,12]. Many studies have reported a
relationship between the number of cases treated in a
hospital and the outcomes of cancer treatment
[12-17]. Moreover, the uniformity of treatment is also
important. Our study was carried out in a hospital that
performs a high volume of dissections for gastric
cancer, with low morbidity and mortality rates. All
participating surgeons were from the same depart-
ment, which minimizes the variation in individual
operating skill and management, and balances the
comparisons between the two groups without bias
from the skill of individual surgeons.
Because G-A is associated with lower mortality and
adequate PS when performed in selected institutions
with sufficient surgical experience and good postopera-
tive management, we recommend that most patients
with curable gastric cancer should undergo total or sub-
total gastrectomy combined with radical lymphadenec-
tomy, a type of surgery compatible with the preservation
of the spleen.
Conclusions
Splenectomy does not benefit patients undergoing radical
resections for gastric cancer, and should not be performed.
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